TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Enrollment • Phase 3Enrollment completion Wed, Jun 30, 2027
Company profile
TuHURA Biosciences, Inc.
Pipeline4 assets
- IFx-2.0IFx-Hu2.0 / Innate Immune System / Personalized Cancer Vaccine / Innate Immune Agonist / OncologyAdvanced or Metastatic Merkel Cell Carcinoma (1st line, adjunctive to pembrolizumab)Phase 3OngoingUnited StatesMerkel Cell Carcinoma of Unknown Primary (MCCUP)Phase 1/Phase 2OngoingUnited States
- TBS-2025KVA12123 / VISTA / Monoclonal Antibody / OncologyAdvanced Solid Tumor CancerPhase 1OngoingUnited StatesmutNPM1 Acute Myeloid Leukemia (AML)Phase 1/Phase 2PlannedUnited States
- Bi-functional ADCsMyeloid-derived suppressor cells (MDSCs) / Antibody-Drug Conjugate (ADC) / OncologySolid TumorsPreclinicalOngoingUnited States
- REM-001Unknown / Photodynamic Therapy / OncologyCutaneous Metastatic Breast Cancer (CMBC)Phase 3OngoingUnited States